Weekly Analysts’ Ratings Updates for 10x Genomics (TXG)

10x Genomics (NASDAQ: TXG) recently received a number of ratings updates from brokerages and research firms:

• 8/10/2026 – 10x Genomics had its price target raised by Piper Sandler from $42.00 to $47.00. They now have a “neutral” rating on the stock.
• 8/10/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $50.00 to $60.00. They now have a “buy” rating on the stock.
• 8/7/2026 – 10x Genomics had its price target raised by Morgan Stanley from $37.00 to $40.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – 10x Genomics was given a new $50.00 price target by Stifel Nicolaus.
• 8/7/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $45.00 to $50.00. They now have a “neutral” rating on the stock.
• 7/17/2026 – 10x Genomics had its price target raised by Leerink Partners from $23.00 to $40.00. They now have a “market perform” rating on the stock.
• 7/15/2026 – 10x Genomics had its “hold” rating reaffirmed by TD Cowen.
• 7/14/2026 – 10x Genomics had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $50.00. They now have a “buy” rating on the stock.
• 7/9/2026 – 10x Genomics had its price target raised by Morgan Stanley from $22.00 to $37.00. They now have an “equal weight” rating on the stock.
• 7/8/2026 – 10x Genomics had its price target raised by Citigroup Inc. from $24.00 to $45.00. They now have a “neutral” rating on the stock.
• 7/1/2026 – 10x Genomics had its price target raised by Piper Sandler from $20.00 to $42.00. They now have a “neutral” rating on the stock.
• 6/24/2026 – 10x Genomics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/24/2026 – 10x Genomics had its price target raised by Barclays PLC from $30.00 to $40.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at 10x Genomics

In other news, CFO Adam Taich sold 15,098 shares of the firm’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $24.44, for a total value of $368,995.12. Following the completion of the transaction, the chief financial officer directly owned 379,898 shares of the company’s stock, valued at $9,284,707.12. This trade represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Shehnaaz Suliman sold 5,723 shares of 10x Genomics stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $32.63, for a total value of $186,741.49. Following the completion of the transaction, the director owned 31,722 shares of the company’s stock, valued at approximately $1,035,088.86. This trade represents a 15.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 91,309 shares of company stock worth $2,581,357 over the last three months. Company insiders own 8.84% of the company’s stock.

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.